Medifast Reports Steep Revenue Decline Amid GLP-1 Pressure

Event summary

  • Q1 2026 revenue dropped 34.3% YoY to $76M, driven by a 44.9% decline in active earning coaches to 14,000.
  • Net loss widened to $2.1M from $0.8M in Q1 2025, with gross profit falling 38.6% to $51.8M.
  • Revenue per active coach rose 19.2% YoY to $5,432, reflecting focus on productive coaches.
  • Company maintains $168.9M in cash with no debt, but forecasts further coach declines in 2026.
  • Q2 2026 revenue guidance set at $60M–$80M, with full-year outlook at $270M–$300M.

The big picture

Medifast's results reflect broader challenges in the weight-loss industry, where GLP-1 medications are disrupting traditional models. The company's focus on metabolic health and coach productivity aims to differentiate its offering, but sustained revenue declines highlight execution risks. With $168.9M in cash and no debt, Medifast has financial flexibility, but its ability to pivot effectively will determine long-term viability.

What we're watching

GLP-1 Competition
How sustained pressure from weight-loss medications will impact Medifast's client acquisition.
Coach Network Viability
Whether the company can stabilize its declining coach base amid strategic realignment.
Cost Efficiency
The pace at which SG&A reductions can offset revenue declines in the near term.